‘True Blood’ star Joe Manganiello shares secret multi-year health battle, organ removal
Joe Manganiello appeared to be the picture of health and fitness throughout his career, but behind-the-scenes, he was…
Dietitians Say These Are the Best Vitamins and Supplements to Stock Up on for Prime Day
Wed, June 24, 2026 at 12:17 AM UTC 12 Supplements on Sale for Prime Day As someone who…
Joe Manganiello ‘plagued by chronic pain’ amid seven-year health battle
Joe Manganiello will open up about suffering from a “cascade of autoimmune-related illnesses” over the course of seven…
Mental Illness Behind Nearly Half of Illness-Related Suicides in India in 2024: SOE 2026, NCRB Data
Chronic illness remains a major factor Chronic or prolonged illness was the second-largest illness-related cause of suicide in…
Accepting ‘sufficient’ can be ‘ideal’ for workers with chronic pain: study
Lowell, MA — Workers with chronic pain can alleviate extra physical and mental fatigue by recognizing that their…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
Mikayla Matthews Says She Has the ‘Worst Anxiety’ About Returning Home to Utah amid Health Struggles
NEED TO KNOW Mikayla Matthews is getting real about health anxiety The Secret Lives of Mormon Wives star,…
Beyond Just ‘Eat Better’ Advice
“Eat better.” It is one of the most common pieces of advice given to people living with chronic…
Pharmacists call for medicine review program to be expanded
When fire brigade officer Colin O’Rourke left hospital after a heart procedure, he ended up on 32 different…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…